35・Development of novel PIM1- or CCNA-targeted therapy for endometrial cancer・Elucidation of the pathogenesis of refractory ovarian cancer・Clarification of the carcinogenesis of GAS and development of specific therapiesOutlook for researchOur research results will hopefully contribute to the development of new prevention and treatment methods. Hence, we aim to reduce the incidence of these cancers and improve treatment outcomes.After obtaining a Ph.D. degree, you can study abroad at foreign countries such as Johns Hopkins University in the US and we actively support your further success.Research subjectChief: Associate Prof. Tsutomu Miyamoto））Outlook for students after graduation2. Placenta Group3. Reproduction GroupMembers of our DepartmentSGI-1776(Pim1 inhibitor) significantly reduced the proliferation of USC cells. (red line).HE staining of GASProf. Tanri ShiozawaDr. David H. Mvunta was a foreign graduate student from Tanzania (from 2013 to 2017). He worked hard and obtained a Ph.D. here.Members of the Gynecologic Cancer Group“Come on and join us!”Summary of ActivityObstetrics and Gynecology (ObGyn) encompasses 4 major academic fields: Obstetrics, Gynecologic On-cology, Reproductive Medicine, and Woman’s healthcare (Fig. 1). ObGyn is the medical field that supports women throughout their lifetime, from birth to the end of life. The uterus and ovaries, which are specific to females, markedly change throughout their lifetime. Pregnancy and delivery are the most dramatic chang-es, in which normal and abnormal conditions may sequentially occur. We want to obtain a clearer under-standing of these changes and diseases specific to women and also perform medical examinations using not only ObGyn, but also, for example, embryology, pathology, and diagnostic imaging.Although medical technologies have rapidly advanced, many issues have yet to be resolved. Among gy-necologic cancers, the morbidity and mortality of endometrial and ovarian cancers are rapidly increasing in Japan. Therefore, the mechanisms underlying endometrial and ovarian carcinogenesis/progression need to be elucidated and new treatment and preventive methods developed based on these mechanisms. Due to advances in perinatal medicine, Japan has become the safest country for pregnancy and delivery. How-ever, the onset mechanisms of hypertensive disorders of pregnancy (HDP) and fetal growth restriction (FGR), which markedly affect perinatal outcomes, remain unclear. Although advances in assisted repro-ductive technologies such as in vitro fertilization and embryo transfer (IVF-ET) have also been achieved, many issues, such as increases in the incidence of chromosomal abnormalities and malformations, have to be overcome in the future.Each of our divisions are actively conducting research to address these issues. ▶Professor: Tanri Shiozawa, M.D., Ph.D.▶Divisions: 1. Gynecologic Cancer Group Summary of ActivityWe are conducting research on refractory gynecological cancers (ovarian clear cell carcinoma OCCC, uterine serous carcinoma USC, and gastric type adeno carcinoma of the cervix GAS).New candidate genes associated with the pathogenesis of OCCC were detected and found to be a potential target for therapy. We have established the world’s first mouse model that develops endometriosis-related cancer by knocking out ARID1A and PTEN, and now analyzing the carcinogenic process of endometriosis with this model.Focusing on the proto-oncogene PIM1, which correlates with the prognosis of USC showing rapid progression and resistance to treatment, we have demonstrated the efficacy of Pim1 inhibitors against USC in vitro and in vivo. We have extensive ex-perience in GAS, which has a poor prognosis and is difficult to diagnose at an early stage, and in the similar benign lesion, lobular endocervical gland hyperplasia (LEGH), and are leading the world in basic and clinical research. Our original preoperative an-alytical diagnosis method has been established, and we are working to develop new treatment methods.（（Chief: Associate Prof. Tsutomu MiyamotoObstetrics and GynecologyObstetrics and GynecologyGynecologic Cancer GroupGynecologic Cancer GroupFrom birthto the end of lifeRevealing and curing refractory gynecological cancers
元のページ ../index.html#37